Growth factors improve latissimus dorsi muscle vascularization and trophicity after cardiomyoplasty

Annals of Thoracic Surgery

Volumn 75, Issue 2, 2003, Pages 549-554

  Zakine, Gilbert ^a   Martinod, Emmanuel ^a   Fornes, Paul ^a   Sapoval, Marc ^a   Barritault, Denis ^a   Carpentier, Alain F ^a   Chachques, Juan Carlos ^a,b  

^a HÔPITAL BROUSSAIS   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; VASCULOTROPIN;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CAPILLARY; CARDIOMYOPLASTY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EPICARDIUM; HISTOLOGY; LATISSIMUS DORSI FLAP; MORPHOMETRICS; MUSCLE ATROPHY; MUSCLE BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; SHEEP;

ANIMALS; CARDIOMYOPLASTY; DEXTRANS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; SHEEP; SKELETAL MUSCLE VENTRICLE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037314785     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)04332-1     Document Type: Article

References (25)

1. Chachques JC, Berrebi A, Carpentier A, et al. Study of muscular and ventricular function in dynamic cardiomyoplasty: a ten-year follow-up. J Heart Lung Transplant 1997; 16:854-68.
2. Jessup M. Dynamic cardiomyoplasty: expectations and resuits. J Heart Lung Transplant 2000;19:68-72.
3. Carpentier A, Chachques JC, Acar C, et al. Dynamic cardiomyoplasty at seven years. J Thorac Cardiovasc Surg 1993;106: 42-54.
4. Magovern GJ, Simpson KA. Clinical cardiomyoplasty: review of the ten-year United States experience. Ann Thorac Surg 1996;61:413-9.
5. Chachques JC, Grandjean PA, Schwartz K, et al. Effect of latissimus dorsi dynamic cardiomyoplasty on ventricular function. Circulation 1988;78(Suppl 3):203-16.
6. Ortega N, L'Faqihi FE, Plouet J. Control of vascular endothelial growth factors angiogenic activity by the extracellular matrix. Biol Cell 1998;90:381-90.
7. Yanagisawa-Miwa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factors. Science 1992;257:1401-3.
8. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol 1992;150:194-203.
9. Desgranges P, Caruelle JP, Carpentier G, Barritault D, Tardieu M. Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses. J Biomed Mater Res 2001;58:1-9.
10. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
11. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-50.
12. Meddahi A, Caruelle JP, Gold L, Rosso Y, Barritault D. New concept in tissue repair: skin as an example. Diabetes Metabol 1996;22:274-8.
13. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998;65: 1540-4.
14. Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000;292:795-802.
15. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001;103: 2138-43.
16. Fu XB, Shen Z, Chen Y, et al. Randomised placebo-controlled trial of use of topical recombinant bovine bFGF for second-degree burns. Lancet 1998;352:1661-4.
17. Robson MC. The role of growth factors in healing of chronic wounds. Wound Rep Reg 1997;5:12-7.
18. Mannion JD, Blood V, Bailey W, et al. The effect of basic fibroblast growth factor on the blood flow and morphologic features of a latissimus dorsi cardiomyoplasty. J Thorac Cardiovasc Surg 1996;111:19-28.
19. Isner JM, Pieczek A, Schainfeld et al. Clinical evidence of angiogenesis after arterial gene transfer of VEGF165 in patients with ischemic limb. Lancet 1996;348:370-4.
20. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, Matsuda H. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002;105:2556-61.
21. Caroll SM, Caroll CM, Stremel RW, Heilman SJ, Tobin GR, Barker JH. Vascular delay of the latissimus dorsi muscle: an essential component of cardiomyoplasty. Ann Thorac Surg 1997;63:1034-40.
22. Al AT, Santamore WP, Chiang BY, Dowling RD, Tobin GR, David Slater A. Vascular delay of the latissimus dorsi provides an early hemodynamic benefit in dynamic cardiomyoplasty. Ann Thorac Surg 1999;67:1304-11.
23. Chachques JC, Tapia M, Radermecker M, et al. Association of latissimus dorsi muscle expansion with electrostimulation before cardiomyoplasty. Ann Thorac Surg 1996;61:138-142.
24. Woo EB, Jarvis JC, Hooper TL, Salmons S. Avoiding ischemia in latissimus dorsi muscle grafts: electrical prestimulation versus vascular delay. Ann Thorac Surg 2002;73:1927-32.
25. Caroll SM, Caroll CM, Stremel RW, et al. Vascular delay and administration of basic fibroblast growth factors augment latissimus dorsi muscle flap perfusion and function. Plast Reconstr Surg 2000;105:964-71.